This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Nicolas Fischer, Ph.D.
CEO at Light Chain Bioscience


After obtaining a PhD in molecular biology, Nicolas joined the group of Greg Winter (2018 Nobel prize for chemistry) at the Medical Research Council in Cambridge (UK) to work on in vitro evolution of proteins and antibody engineering.

At Novimmune since 2002, he led several therapeutic antibody programs. Then, as the Head of Research, he focused on the development of the κλ body bispecific antibody platform which is now the core technology of Light Chain Bioscience where he acts as CEO.

Agenda Sessions

  • Engaging Adaptive and Innate Immune Systems with Bispecific Antibodies Targeting CD28 or CD47